Compile Data Set for Download or QSAR
Report error Found 87 of ph data with Target = 'cAMP-specific 3',5'-cyclic phosphodiesterase 4B'
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120866(US8716478, D253 | US9499570, D253)
Affinity DataIC50: 0.25nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM14359(3-[(2S)-2-[3-cyclopropoxy-4-(difluoromethoxy)pheny...)
Affinity DataIC50: 0.400nMpH: 7.5 T: 2°CAssay Description:PDE4 catalytic activity was monitored by measuring the hydrolysis of [3H]-cAMP to [3H]-AMP using PDE-SPA kit (Amersham International). [3H]-AMP was c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2007
Entry Details Article
PubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120845(US8716478, D231 | US9499570, D231)
Affinity DataIC50: 0.800nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180790(US8865745, 14)
Affinity DataIC50: 0.870nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120855(US8716478, D241 | US9499570, D241)
Affinity DataIC50: 1.10nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120853(US8716478, D239 | US9499570, D239)
Affinity DataIC50: 1.30nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120860(US8716478, D246 | US9499570, D246)
Affinity DataIC50: 1.30nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120862(US8716478, D248 | US9499570, D248)
Affinity DataIC50: 1.70nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120859(US8716478, D245 | US9499570, D245)
Affinity DataIC50: 2nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120856(US8716478, D242 | US9499570, D242)
Affinity DataIC50: 2.20nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM60633(US8865745, 8)
Affinity DataIC50: 2.95nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM255615(US9499570, D141)
Affinity DataIC50: 3.10nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180793(US8865745, 18)
Affinity DataIC50: 3.80nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180779(US8865745, 1)
Affinity DataIC50: 5.13nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120844(US8716478, D238 | US8716478, D230 | US9499570, D23...)
Affinity DataIC50: 5.20nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM60635(US8865745, 17)
Affinity DataIC50: 5.37nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180795(US8865745, 20)
Affinity DataIC50: 5.75nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM60634(US8865745, 9)
Affinity DataIC50: 5.89nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120857(US8716478, D243 | US9499570, D243)
Affinity DataIC50: 6.5nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180780(US8865745, 2)
Affinity DataIC50: 8.13nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180787(US8865745, 11)
Affinity DataIC50: 8.32nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM255614(US9499570, D140)
Affinity DataIC50: 9nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM31647(tetrahydrobenzothiophene (THBT), 21)
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Inhibition of PDE4 is measured using a luminescence-coupled assay system developed by Cambrex. This assay system couples the formation of AMP, derive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2009
Entry Details Article
PubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180791(US8865745, 15)
Affinity DataIC50: 12.6nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180789(US8865745, 13)
Affinity DataIC50: 16.2nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180781(US8865745, 3)
Affinity DataIC50: 17.8nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180782(US8865745, 4)
Affinity DataIC50: 18.2nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120861(US8716478, D247 | US9499570, D247)
Affinity DataIC50: 19nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180785(US8865745, 7)
Affinity DataIC50: 22.4nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM120846(US8716478, D232 | US9499570, D232)
Affinity DataIC50: 23nMpH: 7.5Assay Description:Inhibition of the human PDE4 enzyme, using semi-purified enzyme from human U937 cells. The PDE4 enzyme was partially purified from human U937 myeloid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2017
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM31648(tetrahydrobenzothiophene (THBT), 22)
Affinity DataIC50: 25nMpH: 7.5 T: 2°CAssay Description:Inhibition of PDE4 is measured using a luminescence-coupled assay system developed by Cambrex. This assay system couples the formation of AMP, derive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2009
Entry Details Article
PubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180792(US8865745, 16)
Affinity DataIC50: 33.1nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180794(US8865745, 19)
Affinity DataIC50: 33.1nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180788(US8865745, 12)
Affinity DataIC50: 34.7nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM14360((R)-(-)-3-{2-[(3-cyclopropyloxy-4-difluromethoxy)p...)
Affinity DataIC50: 40nMpH: 7.5 T: 2°CAssay Description:PDE4 catalytic activity was monitored by measuring the hydrolysis of [3H]-cAMP to [3H]-AMP using PDE-SPA kit (Amersham International). [3H]-AMP was c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2007
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM31637(tetrahydrobenzothiophene (THBT), 6)
Affinity DataIC50: 50nMpH: 7.5 T: 2°CAssay Description:Inhibition of PDE4 is measured using a luminescence-coupled assay system developed by Cambrex. This assay system couples the formation of AMP, derive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2009
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM31644(tetrahydrobenzothiophene (THBT), 23)
Affinity DataIC50: 50nMpH: 7.5 T: 2°CAssay Description:Inhibition of PDE4 is measured using a luminescence-coupled assay system developed by Cambrex. This assay system couples the formation of AMP, derive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2009
Entry Details Article
PubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180783(US8865745, 5)
Affinity DataIC50: 70.8nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM31638(tetrahydrobenzothiophene (THBT), 13a)
Affinity DataIC50: 79nMpH: 7.5 T: 2°CAssay Description:Inhibition of PDE4 is measured using a luminescence-coupled assay system developed by Cambrex. This assay system couples the formation of AMP, derive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2009
Entry Details Article
PubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM31649(tetrahydrobenzothiophene (THBT), 24)
Affinity DataIC50: 100nMpH: 7.5 T: 2°CAssay Description:Inhibition of PDE4 is measured using a luminescence-coupled assay system developed by Cambrex. This assay system couples the formation of AMP, derive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2009
Entry Details Article
PubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM180784(US8865745, 6)
Affinity DataIC50: 145nMpH: 7.4 T: 2°CAssay Description:PDE4B1 activity was inhibited by the compounds according to the invention in a modified SPA (scintillation proximity assay) test, supplied by Amersha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/23/2016
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM31636(tetrahydrobenzothiophene (THBT), 4)
Affinity DataIC50: 200nMpH: 7.5 T: 2°CAssay Description:Inhibition of PDE4 is measured using a luminescence-coupled assay system developed by Cambrex. This assay system couples the formation of AMP, derive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2009
Entry Details Article
PubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM31650(tetrahydrobenzothiophene (THBT), 25)
Affinity DataIC50: 398nMpH: 7.5 T: 2°CAssay Description:Inhibition of PDE4 is measured using a luminescence-coupled assay system developed by Cambrex. This assay system couples the formation of AMP, derive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2009
Entry Details Article
PubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM31640(tetrahydrobenzothiophene (THBT), 14)
Affinity DataIC50: 631nMpH: 7.5 T: 2°CAssay Description:Inhibition of PDE4 is measured using a luminescence-coupled assay system developed by Cambrex. This assay system couples the formation of AMP, derive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2009
Entry Details Article
PubMed
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM175783(US9688683, 21)
Affinity DataIC50: 1.00E+3nMpH: 7.8 T: 2°CAssay Description:The test compound or water (control) is mixed with the human recombinant PDE4B1 enzyme (4.8 U) in a buffer consisting of 44.4 mM tris-HCl, 5.28 mM Mg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2018
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM175773(US9688683, 1)
Affinity DataIC50: 1.00E+3nMpH: 7.8 T: 2°CAssay Description:The test compound or water (control) is mixed with the human recombinant PDE4B1 enzyme (4.8 U) in a buffer consisting of 44.4 mM tris-HCl, 5.28 mM Mg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2018
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM175774(US9688683, 2)
Affinity DataIC50: 1.00E+3nMpH: 7.8 T: 2°CAssay Description:The test compound or water (control) is mixed with the human recombinant PDE4B1 enzyme (4.8 U) in a buffer consisting of 44.4 mM tris-HCl, 5.28 mM Mg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2018
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM175775(US9688683, 4)
Affinity DataIC50: 1.00E+3nMpH: 7.8 T: 2°CAssay Description:The test compound or water (control) is mixed with the human recombinant PDE4B1 enzyme (4.8 U) in a buffer consisting of 44.4 mM tris-HCl, 5.28 mM Mg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2018
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM175776(US9688683, 7)
Affinity DataIC50: 1.00E+3nMpH: 7.8 T: 2°CAssay Description:The test compound or water (control) is mixed with the human recombinant PDE4B1 enzyme (4.8 U) in a buffer consisting of 44.4 mM tris-HCl, 5.28 mM Mg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2018
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Anacor Pharmaceuticals

US Patent
LigandPNGBDBM175777(US9688683, 8)
Affinity DataIC50: 1.00E+3nMpH: 7.8 T: 2°CAssay Description:The test compound or water (control) is mixed with the human recombinant PDE4B1 enzyme (4.8 U) in a buffer consisting of 44.4 mM tris-HCl, 5.28 mM Mg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2018
Entry Details
Go to US Patent

Displayed 1 to 50 (of 87 total ) | Next | Last >>
Jump to: